Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose pulsatile sorafenib with AUC-guided escalation in advanced solid tumors
NL-OMON23305Phase 1Recruiting
- Sponsor
- VU University Medical Center
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sorafenib in Nonhematologic neoplasms (2 cohorts), sponsored by VU University Medical Center. Primary endpoints: Maximum tolerated plasma AUC0-12h and Safety and tolerability. Started Sep 2015; status: recruiting.
02
Drugs
sorafenib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON23305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23305.